ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of MR-conditional labeling for the company’s Penta™ 5-column paddle lead for spinal cord stimulation (SCS) therapy to manage chronic pain. The Penta lead, which will be available for use with the company’s Protégé MRI™ system in the U.S., is the only five-column paddle lead on the market that will allow patients to safely undergo head and extremity MRI scans.
For some chronic pain patients, the potential need for future MRI scans has historically acted as a barrier to SCS therapy. Throughout 2015, St. Jude Medical has introduced a series of MR-conditional implantable pulse generators (IPG’s) and leads designed to improve patient access to the latest chronic pain therapy options while preserving the ability to undergo head and extremity MRI scans.
With the newly approved updated labeling, the Penta paddle lead will be available for use with the Protégé MRI system, which is the smallest upgradeable MR-conditional SCS IPG available in the U.S. In an SCS system, an IPG generates electrical energy, which is delivered via leads to nerve fibers along the spine to interrupt pain signals as they travel to the brain, reducing the sensation of pain.
The St. Jude Medical Penta paddle lead is designed to provide physicians the broadest area of lateral stimulation coverage available (9mm), which supports selective stimulation of nerve fibers associated with a patient's pain without needlessly stimulating other areas. The broad coverage of the Penta five-column paddle ensures sufficient stimulation when physicians are faced with anatomical asymmetries or in cases where stimulation is needed in very specific clusters of nerve fibers. Such specific targeting allows physicians to tailor therapy to a patient’s unique pain pattern.
"We are excited to receive MR-conditional labeling approval for our Penta paddle lead alongside the recent approval of the Protégé MRI system and MR-conditional labeling for our Octrode™ percutaneous leads,” said Eric S. Fain, M.D., group president of St. Jude Medical. “When taken together, the approvals of these products in our chronic pain portfolio represent a critical component to growing our neuromodulation business and improving access to our industry-leading chronic pain therapies for patients who may need future head and extremity MRI scans.”
Chronic pain affects more than 100 million Americans, an incidence rate which outpaces heart disease, cancer and diabetes combined. In total, the condition costs the American population 515 million workdays annually and generates upwards of 40 million visits to physicians each year. SCS therapy can offer proven, meaningful chronic pain relief for many patients while improving quality of life and reducing or even eliminating a patient’s use of pain medication.
About the St. Jude Medical Chronic Pain Portfolio
Chronic
pain affects approximately 1.5 billion people worldwide, more than heart
disease, cancer and diabetes combined. The condition can negatively
impact mood, personal relationships, work productivity, and activities
of daily living. St. Jude Medical offers multiple solutions for patients
to manage debilitating chronic pain, including spinal cord stimulation
(SCS) and radiofrequency ablation (RFA).
About St. Jude Medical
St. Jude Medical is a global medical
device manufacturer dedicated to transforming the treatment of some of
the world’s most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and improve
lives of patients around the world. Headquartered in St. Paul, Minn.,
St. Jude Medical has four major clinical focus areas that include
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com
or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that involve risks and uncertainties. Such
forward-looking statements include the expectations, plans and prospects
for the Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made by
the Company are based upon management’s current expectations and are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include market conditions and
other factors beyond the Company’s control and the risk factors and
other cautionary statements described in the Company’s filings with the
SEC, including those described in the Risk Factors and Cautionary
Statements sections of the Company’s Annual Report on Form 10-K for the
fiscal year ended January 3, 2015 and Quarterly Report on Form 10-Q for
the fiscal quarter ended April 4, 2015. The Company does not intend to
update these statements and undertakes no duty to any person to provide
any such update under any circumstance.
